Alkylating agents
Chemotherapy + Radiation Therapy for Brain Cancer
This trial is studying how well different combinations of chemotherapy and radiation therapy work in treating patients with non-germinomatous germ cell tumors that have not spread to other parts of the brain or body.
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Popular Filters
Trials for Cancer Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials for Adenocarcinoma Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Trials for Metastatic Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Genitourinary Cancers
This trial is studying a combination of two drugs, Nivolumab and Ipilimumab, as a possible treatment for rare genitourinary cancers. Bladder and upper tract carcinomas with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas, and any genitourinary carcinoma with neuroendocrine differentiation are being studied. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time.
Trials With No Placebo
Behavioural Intervention
Virtual Active Surveillance for Testicular Cancer
This trial is testing WATChmAN, an online system for testicular cancer patients to manage their follow-up care virtually. It aims to make follow-ups easier and more convenient by reducing the need for regular hospital visits. Patients will receive reminders, check their results, and communicate with doctors through the platform.
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Frequently Asked Questions
Introduction to testicular cancer
What are the top hospitals conducting testicular cancer research?
When it comes to clinical trials in the field of testicular cancer, several leading hospitals are making significant contributions. In Irvine, California, the University of California is actively conducting two trials focused on this specific type of cancer. While still relatively new to the field with only two all-time trials recorded since 2018, their dedication to advancing knowledge and treatment options for testicular cancer is commendable. Across the border in Toronto's Princess Margaret Hospital at University Health Network, researchers have also embraced this important cause. They currently have two active testicular cancer trials underway and have been committed to investigating this disease since recording their first trial in 2005.
Meanwhile, Memorial Sloan Kettering Cancer Center in New york has joined the ranks with its own focus on advancing understanding and treatment options for testicular cancer. The center is currently running two active clinical trials dedicated to this condition while having conducted a total of five all-time studies since initiating their first trial back in 2011.
In Boston's Brigham and Women's Hospital as well as START Midwest located in Grand Rapids, both institutions are devotedly contributing by each carrying out one active testicular cancer trial respectively. Although they may be newer players within this medical landscape with just one recorded trial each starting from either2022 or2023 so far; these hospitals' commitment clearly demonstrates that even small steps can lead us toward groundbreaking discoveries for improved outcomes against such challenging diseases.
The collective efforts made by these top-notch medical centers across different locations stand testament not only to scientific progress but also speak volumes about unwavering determination towards improving the lives of those affected by testicular cancer worldwide. By coming together through research initiatives and engaged patient participation, they're fostering hope for brighter futures where more effective treatments become available ensuring better quality life amongst countless individuals
Which are the best cities for testicular cancer clinical trials?
When it comes to testicular cancer clinical trials, several cities show promise as hubs for research and advancement. Toronto, Ontario leads the way with three active trials investigating treatments like SGN-ALPV, WATChmAN Active Surveillance, and Low-dose computed tomography (LDCT). Houston, Texas also has three ongoing studies focusing on Pharmacological Study, Stem Cell Transplant, and cisplatin. Boston, Massachusetts follows closely behind with two active trials exploring Electromagnetic Guided Laparoscopy + Ultrasound and Pharmacological Study. Irvine, California and New york City each have two active trials in progress as well. These cities provide opportunities for individuals fighting testicular cancer to participate in cutting-edge clinical research that may lead to improved treatment options and outcomes.
Which are the top treatments for testicular cancer being explored in clinical trials?
Testicular cancer research is making strides in clinical trials, exploring innovative treatments with promising potential. Leading the way is Goal-Focused Emotion-Regulation Therapy (GET), currently being tested in one active trial dedicated to testicular cancer. Another notable contender is SGN-ALPV, undergoing evaluation in a single ongoing trial since its first listing in 2022. Additionally, WATChmAN Active Surveillance showcases promise as an alternative approach for treatment, also supported by one active and all-time testicular cancer trials since 2017. With each study conducted, researchers move closer to revolutionizing the landscape of testicular cancer treatment options available to patients worldwide.
What are the most recent clinical trials for testicular cancer?
Recent clinical trials offer promising avenues for the treatment of testicular cancer. ATLCAR.CD30, an ongoing Phase 2 trial, has shown potential in improving outcomes for patients with this form of cancer. In a separate Phase 1 study, SGN-ALPV exhibited encouraging results as a therapeutic option. Additionally, Gallium Ga 68 FAPi-46 demonstrated promise in early-phase research. These innovative approaches aim to enhance treatment options and ultimately improve the prognosis for individuals battling testicular cancer.
What testicular cancer clinical trials were recently completed?
A notable clinical trial investigating treatment options for testicular cancer has recently concluded. In December 2016, the Ludwig Institute for Cancer Research successfully completed a trial evaluating the effectiveness of Tremelimumab. This study aimed to uncover potential therapeutic benefits and improve outcomes for individuals with testicular cancer. The completion of this trial represents an important step forward in advancing our understanding and management of this particular form of cancer.